C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3018% above fair value
$2.76−0.01 (-0.36%)
Close on Nov 13, 2026Market cap $339.55MP/E –Yield –
C4 Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
C4 Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$79.63M. For fiscal 2025 it was -$98.69M. The highest annual figure on record is $55.61M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$98.69M | – |
| FY2024 | Dec 31, 2024 | -$65.16M | – |
| FY2023 | Dec 31, 2023 | -$106.84M | – |
| FY2022 | Dec 31, 2022 | -$105.94M | – |
| FY2021 | Dec 31, 2021 | -$86.97M | – |
| FY2020 | Dec 31, 2020 | -$67.25M | -220.9% |
| FY2019 | Dec 31, 2019 | $55.61M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.97M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.57M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.21M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$30.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.20M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.60M | – |
| Q4 FY2021 | Dec 31, 2021 | -$25.67M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.59M | – |
| Q3 FY2020 | Sep 30, 2020 | -$14.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.30M | – |
See a number that looks wrong?